Key Targets and Relevant Inhibitors for the Drug Discovery of Tuberculosis

doi:10.2174/1389450111314060009

CORC > 上海药物研究所 > 中国科学院上海药物研究所 > 药物发现与设计中心

	Key Targets and Relevant Inhibitors for the Drug Discovery of Tuberculosis
	Xiong, Xiuming 2,3; Xu, Zhijian3 ; Yang, Zhuo 3; Liu, Yingtao 3; Wang, Di 4; Dong, Mei 4; Parker, Emily J.1,5; Zhu, Weiliang2,3
刊名	CURRENT DRUG TARGETS
	2013-06
卷号	14 期号:6 页码:676-699
关键词	Antimycobacterial dormant drug-resistant inhibitors Mycobacterium tuberculosis new targets
ISSN号	1389-4501
DOI	10.2174/1389450111314060009
文献子类	Article
英文摘要	Tuberculosis (TB) is an infectious disease caused by the pathogen Mycobacterium tuberculosis (M. tuberculosis), killing about two million people worldwide each year. An increase in the prevalence of drug-resistant strains of M. tuberculosis in the past decades has renewed focus on the development of new drugs that can treat both drug-sensitive and resistant TB infections. M. tuberculosis evades the host immune system and drug regimes by entering dormant phase within macrophage. As a consequence, there is a pressing need for new vaccines and antimicrobials to treat persistent infections. As clinically used antibiotics target very few essential functions of mycobacterium, it is rational that identification of new targets that are essential for bacterial growth and survival can serve as starting point for designing of novel drugs to cure both drug-sensitive and resistant TB infections. With the development of molecular biology and structural biology and the availability of the genome sequence of M. tuberculosis, some success has been achieved in the identification of new targets in M. tuberculosis and their relevant inhibitors. This review summarizes about ninety important targets that participate in a range of diverse physiological processes in M. tuberculosis and seven new drugs currently in clinical phase 2 or 3 trials. In addition, promising inhibitors with novel mechanisms of action and clinical vaccine candidates are highlighted.
资助项目	Ministry of Science and Technology[2010DFB33970] ; Ministry of Science and Technology[2012AA01A305] ; National Natural Science Foundation[21021063] ; National Natural Science Foundation[81273435] ; National Natural Science Foundation[81271777]
WOS关键词	NONREPLICATING MYCOBACTERIUM-TUBERCULOSIS ; PEPTIDE DEFORMYLASE INHIBITORS ; WALL ARABINAN BIOSYNTHESIS ; SALICYLATE SYNTHASE MBTI ; STRUCTURE-BASED DESIGN ; DNA-LIGASE RV3014C ; PROTEIN-KINASE-G ; CRYSTAL-STRUCTURE ; CELL-WALL ; PANTOTHENATE SYNTHETASE
WOS研究方向	Pharmacology & Pharmacy
语种	英语
出版者	BENTHAM SCIENCE PUBL LTD
WOS记录号	WOS:000318689000009
内容类型	期刊论文
源URL	[http://119.78.100.183/handle/2S10ELR8/277607]
专题	药物发现与设计中心
通讯作者	Parker, Emily J.
作者单位	1.Univ Canterbury, Dept Chem, Christchurch 1, New Zealand; 2.Nanchang Univ, Coll Med, Nanchang 330066, Jiangxi, Peoples R China; 3.Chinese Acad Sci, Shanghai Inst Mat Med, Drug Discovery & Design Ctr, Shanghai 201203, Peoples R China; 4.309 Hosp Chinese Peoples Liberat Army, Dept Clin Lab, Beijing 100091, Peoples R China; 5.Univ Canterbury, Biomol Interact Ctr, Christchurch 1, New Zealand
推荐引用方式 GB/T 7714	Xiong, Xiuming,Xu, Zhijian,Yang, Zhuo,et al. Key Targets and Relevant Inhibitors for the Drug Discovery of Tuberculosis[J]. CURRENT DRUG TARGETS,2013,14(6):676-699.
APA	Xiong, Xiuming.,Xu, Zhijian.,Yang, Zhuo.,Liu, Yingtao.,Wang, Di.,...&Zhu, Weiliang.(2013).Key Targets and Relevant Inhibitors for the Drug Discovery of Tuberculosis.CURRENT DRUG TARGETS,14(6),676-699.
MLA	Xiong, Xiuming,et al."Key Targets and Relevant Inhibitors for the Drug Discovery of Tuberculosis".CURRENT DRUG TARGETS 14.6(2013):676-699.